A detailed history of Deutsche Bank Ag\ transactions in Erasca, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 51,599 shares of ERAS stock, worth $139,317. This represents 0.0% of its overall portfolio holdings.

Number of Shares
51,599
Previous 32,053 60.98%
Holding current value
$139,317
Previous $75,000 86.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.17 - $3.28 $42,414 - $64,110
19,546 Added 60.98%
51,599 $140,000
Q2 2024

Aug 14, 2024

BUY
$1.79 - $2.63 $11,545 - $16,963
6,450 Added 25.19%
32,053 $75,000
Q1 2024

May 15, 2024

SELL
$1.67 - $2.55 $2,850 - $4,352
-1,707 Reduced 6.25%
25,603 $52,000
Q4 2023

Feb 14, 2024

SELL
$1.67 - $2.49 $20,664 - $30,811
-12,374 Reduced 31.18%
27,310 $58,000
Q3 2023

Nov 09, 2023

BUY
$1.97 - $2.91 $28,096 - $41,502
14,262 Added 56.1%
39,684 $78,000
Q2 2023

Aug 14, 2023

SELL
$2.57 - $3.3 $94,288 - $121,070
-36,688 Reduced 59.07%
25,422 $70,000
Q1 2023

May 15, 2023

BUY
$2.74 - $4.44 $73,875 - $119,711
26,962 Added 76.71%
62,110 $186,000
Q4 2022

Feb 13, 2023

BUY
$3.89 - $8.57 $35,262 - $77,687
9,065 Added 34.75%
35,148 $151,000
Q3 2022

Nov 14, 2022

SELL
$5.82 - $10.68 $25,235 - $46,308
-4,336 Reduced 14.25%
26,083 $203,000
Q2 2022

Aug 11, 2022

SELL
$4.58 - $8.72 $27,228 - $51,840
-5,945 Reduced 16.35%
30,419 $169,000
Q1 2022

May 13, 2022

BUY
$8.6 - $15.48 $197,413 - $355,343
22,955 Added 171.19%
36,364 $312,000
Q4 2021

Feb 11, 2022

BUY
$12.51 - $22.75 $8,656 - $15,743
692 Added 5.44%
13,409 $209,000
Q3 2021

Nov 04, 2021

BUY
$17.43 - $24.34 $221,657 - $309,531
12,717 New
12,717 $270,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $330M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.